Holen Sie sich die Stockscreener-App
24.45
3.10%
-0.86
Schlusskurs vom Vortag:
$25.31
Offen:
$25.14
24-Stunden-Volumen:
2.91M
Relative Volume:
1.93
Marktkapitalisierung:
$1.60B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-130.41M
KGV:
-10.92
EPS:
-2.24
Netto-Cashflow:
$-67.76M
1W Leistung:
+60.19%
1M Leistung:
+44.35%
6M Leistung:
+363.61%
1J Leistung:
+309.43%
1-Tages-Spanne:
$23.85
$25.18
1-Wochen-Bereich:
$13.69
$25.77
52-Wochen-Spanne:
$3.5001
$25.77
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Firmenname
Monte Rosa Therapeutics Inc
Sektor
Branche
Telefon
617-949-2643
Adresse
321 HARRISON AVENUE, BOSTON
Vergleichen Sie GLUE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
24.54 | 1.65B | 0 | -130.41M | -67.76M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
800.86 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
407.50 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
805.94 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
339.86 | 35.45B | 4.98B | 69.59M | 525.67M | 0.5197 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | Eingeleitet | UBS | Buy |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-10-14 | Eingeleitet | SVB Leerink | Mkt Perform |
Alle ansehen
Monte Rosa Therapeutics Inc Aktie (GLUE) Neueste Nachrichten
Monte Rosa Therapeutics Prices Underwritten Public Offering Of $300 Mln Of Shares - Nasdaq
Why Monte Rosa Therapeutics Inc. stock is considered a top pickWeekly Investment Recap & Risk Managed Investment Strategies - ulpravda.ru
Monte Rosa Therapeutics prices $300 million public offering - Investing.com
Biotech Monte Rosa is selling $300M in new shares to investors - Stock Titan
Monte Rosa Therapeutics announces pricing of $300 million underwritten public offering at $24.00 per share - MarketScreener
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering - GlobeNewswire
How institutional buying supports Monte Rosa Therapeutics Inc. stockJuly 2025 Highlights & Daily Market Momentum Tracking - ulpravda.ru
Can Monte Rosa Therapeutics Inc. stock beat analyst upgradesJuly 2025 Highlights & AI Forecasted Stock Moves - ulpravda.ru
Will Monte Rosa Therapeutics Inc. stock attract more institutional investorsWeekly Investment Summary & Free AI Powered Buy and Sell Recommendations - ulpravda.ru
Is Monte Rosa Therapeutics Inc. stock a safe investment in uncertain marketsJuly 2025 Snapshot & Accurate Buy Signal Notifications - ulpravda.ru
GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug - Finviz
Why Monte Rosa Therapeutics Inc. stock is a must watch in 2025Weekly Profit Summary & Community Trade Idea Sharing - ulpravda.ru
Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
GLUE Stock Receives Analyst Rating Update with Raised Price Targ - GuruFocus
Monte Rosa Therapeutics (GLUE) is on the Move, Here's Why the Trend Could be Sustainable - sharewise.com
GLUE Stock: Guggenheim Maintains Buy Rating, Raises Price Target - GuruFocus
Monte Rosa Therapeutics (NASDAQ:GLUE) Given New $34.00 Price Target at Guggenheim - MarketBeat
Monte Rosa Therapeutics: Competitive MRT-8102 Results Offer Additional Platform Validation - Seeking Alpha
Monte Rosa Therapeutics Reaches Analyst Target Price - Nasdaq
Monte Rosa Therapeutics dips after $200 mln equity offering launched - TradingView — Track All Markets
Zacks Research Upgrades Monte Rosa Therapeutics (NASDAQ:GLUE) to Strong-Buy - MarketBeat
Monte Rosa Therapeutics launches $200 million public offering By Investing.com - Investing.com Nigeria
Monte Rosa Therapeutics launches $200M public equity offering - MSN
Monte Rosa Therapeutics (GLUE) upgraded to strong buy: Here's why - MSN
The Great Thaw: Biotech Fundraising Surges as Monte Rosa and Genelux Tap Reopening Markets - FinancialContent
Monte Rosa Therapeutics Ends Current ATM Equity Program - TipRanks
Monte Rosa Therapeutics launches $200 million public offering - Investing.com
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Biotech working on new medicines moves to raise $200M - Stock Titan
Monte Rosa Therapeutics (GLUE) Soars on Promising Inflammation Drug Data - RagingBull
Monte Rosa Therapeutics (GLUE) Upgraded to Strong Buy: Here's Why - sharewise.com
Cardio works out for Monte Rosa in NEK7 phase I - BioWorld MedTech
Monte Rosa Therapeutics price target raised to $37 from $26 at Wedbush - TipRanks
Monte Rosa Therapeutics (NASDAQ:GLUE) Hits New 12-Month HighShould You Buy? - MarketBeat
GLUE: MRT-8102 achieved robust hsCRP and fibrinogen reductions with favorable safety in phase I - TradingView — Track All Markets
Why Is Monte Rosa Therapeutics Stock Skyrocketing Wednesday?Monte Rosa Therapeutics (NASDAQ:GLUE) - Benzinga
Monte Rosa Therapeutics: Early MRT-8102 hsCRP Data Underscore Differentiated NLRP3 Opportunity and Attractive Risk-Reward Supporting Buy Rating - TipRanks
Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday - Benzinga
Monte Rosa Therapeutics stock hits 52-week high at $21.89 - Investing.com
Monte Rosa Therapeutics Shares Phase 1 MRT-8102 Data Showing 85% hsCRP Drop, No Safety Flags - MarketBeat
GLUE Hits New High On Positive Phase 1 Data For MRT-8102 In Cardiovascular Risk Participants - RTTNews
Here’s Why Monte Rosa Therapeutics Stock (GLUE) Rocketed Today - TipRanks
Monte Rosa’s MRT-8102 shows promising results in reducing inflammation By Investing.com - Investing.com Nigeria
Why Did GLUE Stock Surge Over 50% In Premarket Today? - Stocktwits
Did Monte Rosa’s Interim MRT-8102 Data Reveal a Turning Point for Its Molecular Glue Platform (GLUE)? - simplywall.st
Monte Rosa reports positive Phase 1 data for MRT-8102 - TipRanks
Monte Rosa’s MRT-8102 shows promising results in reducing inflammation - Investing.com India
Monte Rosa Therapeutics Reports Positive Interim Data from Phase 1 Study of MRT-8102 in Reducing Inflammation in Cardiovascular Disease Risk Patients - Quiver Quantitative
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 - TradingView — Track All Markets
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects - The Manila Times
Monte Rosa (GLUE) Stock Pre-Market (+8.7%): Positive Phase 1 Data for MRT-8102 - Trefis
Finanzdaten der Monte Rosa Therapeutics Inc-Aktie (GLUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):